You are here

  • Home
  • Archive
  • Volume 9, Issue 5
  • Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer

Article metrics

Article menu
XML
Clinical/translational cancer immunotherapy
Original research
Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer

 

Online download statistics by month:

Online download statistics by month: May 2021 to March 2024

AbstractFullPdf
May 2021700701220
Jun 202121421474
Jul 202116116151
Aug 202113613638
Sep 202115915940
Oct 202113113146
Nov 202111411554
Dec 202110410437
Jan 2022869152
Feb 2022717547
Mar 2022778046
Apr 2022626647
May 202210110452
Jun 2022666935
Jul 2022747749
Aug 2022828853
Sep 2022495019
Oct 2022778348
Nov 2022666633
Dec 2022868838
Jan 2023555522
Feb 2023828223
Mar 2023555649
Apr 2023586028
May 2023394126
Jun 2023414127
Jul 2023363622
Aug 2023373722
Sep 2023282811
Oct 2023535329
Nov 2023585830
Dec 2023585825
Jan 2024414330
Feb 2024717127
Mar 2024757697
Total340334531547